These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 12422563

  • 1. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
    Anglès A, Bagheri H, Saivin S, Montastruc JL.
    Therapie; 2002; 57(4):408-10. PubMed ID: 12422563
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Peak-dose dyskinesia; an acceptable price for mobility in late-stage Parkinson's disease?
    Wenzelburger R.
    Clin Neurophysiol; 2005 Sep; 116(9):1997-8. PubMed ID: 16055380
    [No Abstract] [Full Text] [Related]

  • 5. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)].
    Allain H, Van den Driessche J, Menault F, Pape D, Reymann JM, Bentue-Ferrer D.
    Sem Hop; 2005 Sep; 56(5-6):277-82. PubMed ID: 6243802
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Pharmacotherapy of a geriatric patient with Parkinson's disease].
    Klemmer JM, Schmitz S, Roth S, Simons S, Reineking N, Eisert A, Lang B, Jaehde U.
    Med Monatsschr Pharm; 2007 Nov; 30(11):411-4. PubMed ID: 18062332
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Sexual delinquency and Parkinson's disease].
    Berger Ch, Mehrhoff FW, Beier KM, Meinck HM.
    Nervenarzt; 2003 Apr; 74(4):370-5. PubMed ID: 12707708
    [Abstract] [Full Text] [Related]

  • 13. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E, Hirt D, Markstein R, Vigouret JM.
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract] [Full Text] [Related]

  • 14. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B, Subramanian T.
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication.
    Canesi M, Antonini A, Mariani CB, Tesei S, Zecchinelli AL, Barichella M, Pezzoli G.
    J Neural Transm (Vienna); 1999 Aug; 106(9-10):925-9. PubMed ID: 10599874
    [Abstract] [Full Text] [Related]

  • 18. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ, Metman LV, Chase TN.
    Adv Neurol; 2003 Aug; 91():251-7. PubMed ID: 12442683
    [No Abstract] [Full Text] [Related]

  • 19. [Treatment of later phases of Parkinson disease].
    Tison F.
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F85-8. PubMed ID: 18680823
    [No Abstract] [Full Text] [Related]

  • 20. [Dangers in drug therapy of Parkinson's disease].
    Gehlen W.
    Z Allgemeinmed; 1975 Nov 30; 51(33):1543-4. PubMed ID: 1210361
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.